MRI Imaging for Suspected Placenta Accreta
Customize your policy alerts
Sign up for all parklandcommunityhealthplan policy alerts
Know when parklandcommunityhealthplan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy establishes medical-necessity and prior-authorization criteria for pelvic MRI used to evaluate suspected placenta accreta spectrum, including accreta, increta, and percreta. It applies to clinical reviews, authorization determinations, and claim adjudication for PCHP STAR and CHIP members.
No material clinical or coverage changes in this revision.
Coverage Criteria
MRI pelvis for suspected PAS
MRI of the pelvis may be considered medically necessary when all of the following criteria are met.
Medical necessity for MRI pelvis
Clinical risk factors for PAS
- Prior cesarean delivery
- Placenta previa
- Prior uterine surgery or curettage
- Asherman syndrome
- Low-lying placenta
Indeterminate or incomplete ultrasound findings
- Ultrasound findings are equivocal or inconclusive for PAS
- The placental-myometrial interface cannot be adequately visualized
- Posterior placenta previa limits ultrasound visualization
- Clinical risk factors and ultrasound findings are discordant
- Assessment of invasion depth is needed in suspected placenta percreta, including evaluation of parametrial involvement or bladder invasion
Expected impact on clinical management
- Results will influence delivery planning
- Results will influence surgical planning
- Results will influence determination of multidisciplinary care needs
- Results will influence selection of a delivery facility with appropriate maternal-fetal medicine and surgical capabilities
MRI of the pelvis is not medically necessary for routine screening of an asymptomatic pregnancy or when used as the initial evaluation without a prior targeted obstetric ultrasound. It is also not medically necessary for a low-risk pregnancy with normal ultrasound findings and no clinical concern for placenta accreta spectrum (PAS).
MRI should not be used as the sole diagnostic test for PAS. It is intended as an adjunct to targeted obstetric ultrasound when ultrasound findings are indeterminate or incomplete.
MRI is not medically necessary when it is requested as a repeat study without evidence of a change in clinical status or when the request does not document how the MRI results will affect clinical management.
Covered Indications
Suspected placenta accreta spectrum with clinical risk factors and indeterminate or incomplete ultrasound findings
Covered when all of the following are met:
MRI indication for suspected PAS
- PAS risk factor: At least one listed clinical risk factor is present.>=1
- Ultrasound limitation or uncertainty: At least one listed ultrasound finding is equivocal, incomplete, technically limited, discordant, or requires assessment of suspected percreta invasion depth.>=1
- Management impact: Results are expected to influence delivery planning, surgical planning, multidisciplinary care, or delivery-facility selection.>=1
Applicable MRI Pelvis Codes
Provider Submission and Review Guidance
Submit prior authorization request
Prior authorization is required for covered pelvic MRI requests under this policy. The request must demonstrate the applicable PAS risk factors, indeterminate or incomplete ultrasound findings, expected management impact, and all required supporting documentation.
Include required authorization documentation
Authorization requests must include the required clinical and supporting records for review.
- Obstetric ultrasound report
- Maternal-fetal medicine consultation notes, if available
- Documentation of PAS risk factors
- Estimated gestational age
- Clinical rationale explaining why MRI is needed beyond ultrasound findings
- Documentation describing how MRI results will affect treatment or delivery planning
Avoid not medically necessary scenarios
Requests may be denied when MRI is used for routine screening of an asymptomatic pregnancy, as the initial evaluation without a prior targeted obstetric ultrasound, for a low-risk pregnancy with normal ultrasound findings and no clinical concern for PAS, or as a repeat study without evidence of changed clinical status. Requests lacking documentation demonstrating how MRI results will impact management are also not medically necessary, and MRI should not be used as the sole diagnostic test for PAS.
Clinical Background
Placenta accreta spectrum (PAS) comprises abnormal adherence or invasion of placental villi into the myometrium and includes placenta accreta, placenta increta, and placenta percreta. Pelvic MRI may supplement targeted obstetric ultrasound when findings are indeterminate or incomplete, particularly when assessment of invasion depth or parametrial or bladder involvement is needed. Imaging can support delivery and surgical planning, multidisciplinary care, and selection of an appropriately equipped facility.
Placenta Accreta Spectrum Definitions
Repeat MRI Limitations
Contrast Use During Pregnancy
Use gadolinium contrast only when justified
Gadolinium contrast is generally not recommended during pregnancy unless the expected benefit clearly outweighs the potential fetal risks.
Excluded Uses
MRI is not covered as medically necessary for routine screening of asymptomatic pregnancies, as the initial evaluation without a prior targeted obstetric ultrasound, or for low-risk pregnancies with normal ultrasound findings and no clinical concern for PAS. Repeat MRI without a change in clinical status, requests lacking documentation of management impact, and use of MRI as the sole diagnostic test for PAS are also excluded.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.